Clinical trials: Toripalimab
Breast Neoplasms
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
This study will evaluate the efficacy, safety and tolerability of RC48-ADC with JS001 compared with RC48-ADC in endocrine-resistant hormone receptor (HR) positive, human epidermal growth factor receptor (HER)2-low advanced breast…
- Trial name
- NCT06105008
- Testing
- Disitamab Vedotin, Toripalimab
- Where
- 3 sites in China
- Sponsor
- RemeGen Co., Ltd.
Breast Cancer
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer
- Trial name
- NCT06227117
- Testing
- Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- RemeGen Co., Ltd.
Urothelial Carcinoma, HER2-expressing
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
This is a Phase 3, Open-Label, Multicenter, Randomised, Controlled Study designed to compare RC48-ADC in Combination With JS001 to Chemotherapy Alone in Previously Untreated HER2-Expressing Unresectable Locally Advanced or…
- Trial name
- NCT05302284
- Testing
- RC48-ADC, Toripalimab, Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 452 people
- Sponsor
- RemeGen Co., Ltd.
Cancer
Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy
YH004 is a humanized monoclonal antibody that specifically binds to 4-1BB, and acts as an agonist against 4-1BB. This first in human study of YH004 is designed to establish the maximum tolerated dose (MTD) and/or the recommended…
- Trial name
- NCT05040932
- Testing
- YH004
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Small Cell Lung Cancer
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.
This is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006…
- Trial name
- NCT07559929
- Testing
- DXC006, Toripalimab, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hangzhou DAC Biotechnology Co., Ltd.
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with…
- Trial name
- NCT07111832
- Testing
- SHR-A1811 for Injection, SHR-1316 Injection, Toripalimab Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastric Type Adenocarcinoma (GAS) With STK11 Mutation
A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced Gastric-type Endocervical Adenocarcinoma with STK11 mutations.
- Trial name
- NCT06124963
- Testing
- WX390, Toripalimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
HCC, NSCLC Stage IIIB
A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC
This is an Open-label, Non-Randomized, Multi-center Phase 2 study of YH001 in Combination with Toripalimab，The study is designed to determine the safety ，tolerability and antitumor activity of YH001 in combination with…
- Conditions
- HCC, NSCLC Stage IIIB, NSCLC Stage IV
- Trial name
- YH001 (NCT05212922)
- Testing
- YH001 + Toripalimab
- Where
- 22 sites in Armenia, Australia and 3 more
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Advanced Solid Tumor
CAN1012 Combined With PD-1 in Patients With Solid Tumors
This is a Phase Ia/IIb, open-label, first-in-human, multicenter, single-arm, dose escalation study of intratumoral CAN1012 combined with PD-1 in patients with Unresectable or Metastatic Advanced Solid Tumors who have exhausted…
- Trial name
- NCT06410703
- Testing
- CAN1012
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Canwell Biotech Limited
Advanced Tumours
Study of LM-061 in Subjects in Advanced Tumors
This is a phase I, open-label, dose escalation study to evaluate the safety, tolerability, PK, and preliminary efficacy of LM-061 in subjects with advanced tumors.
- Trial name
- NCT04737122
- Testing
- LM-061, Toripalimab
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- LaNova Medicines Limited
Melanoma, Pancreatic Ductal Adenocarcinoma
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT05031494
- Testing
- YH003, Toripalimab, Nab-paclitaxel
- Where
- 2 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Eucure (Beijing) Biopharma Co., Ltd
Solid Tumors, Neuroendocrine Tumors
HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part 1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability, PK/PD and preliminary efficacy of in patients…
- Conditions
- Solid Tumors, Neuroendocrine Tumors, CRC
- Trial name
- NCT05167071
- Testing
- HBM4003, Toripalimab, Tislelizumab
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Harbour BioMed (Guangzhou) Co. Ltd.
NSCLC, Stage III
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
This is a phase II trial assessing the efficacy and safety of GFH018 and Toripalimab in combination with concurrent chemoradiotherapy (cCRT) in patients with unresectable, locally advanced, Stage III non-small cell lung cancer…
- Trial name
- NCT05386888
- Testing
- GFH018, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
The purpose of this study is to evaluate the efficacy and safety of perioperative Disitamab Vedotin plus Toripalimab and XELOX versus Disitamab Vedotin plus Toripalimab versus XELOX in subjects with HER2-expressing resectable…
- Trial name
- NCT06155383
- Testing
- Capecitabine, oxaliplatin, Disitamab Vedotin
- Where
- 11 sites in China
- Volunteers
- 90 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Neuroendocrine Carcinoma
A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma
To evaluate the efficacy of Surufatnib combined with Toripalimab compared with FOLFIRI in the treatment of advanced neuroendocrine carcinoma
- Trial name
- NCT05015621
- Testing
- Surufatinib plus Toripalimab, 5-fluorouracil, Calcium folinate and Irinotecan
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Hutchison Medipharma Limited
Advanced Solid Tumors
Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
This is a phase II, single arm, open-label, multicenter study to evaluate the efficacy and safety of Surufatinib single agent or Surufatinib combined with Toripalimab in patients with advanced solid tumors.
- Trial name
- NCT04169672
- Testing
- Surufatinib, Toripalimab
- Where
- 2 sites in China
- Volunteers
- 248 people
- Sponsor
- Hutchison Medipharma Limited
Advanced Urothelial Carcinoma
9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
This is a phase Ib/II, open-label, multicenter clinical study to evaluate the safety, tolerability, efficacy, pharmacokinetics and immunogenicity of 9MW2821 combined with Toripalimab injection in subjects with local advanced or…
- Trial name
- NCT06079112
- Testing
- 9MW2821, Toripalimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Advanced or Metastatic Solid Tumors
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
- Trial name
- NCT06389526
- Testing
- CHS-1000, Toripalimab
- Volunteers
- 48 people
- Sponsor
- Coherus Oncology, Inc.
Gastric Adenocarcinoma
JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a multicenter, randomized, open-label, controlled Phase III clinical trial aimed at evaluating the efficacy and safety of JS107 combined with toripalimab XELOX versus sintilimab combined with XELOX as first-line…
- Trial name
- NCT07584135
- Testing
- Injection JS107&Toripalimab& Oxaliplatin Injection& Capecitabine, Sintilimab& Oxaliplatin Injection& Capecitabine
- Where
- China
- Volunteers
- 600 people
- Sponsor
- NingBo Junyan Hongshi Biosciences Co., Ltd
Advanced Solid Tumors
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
this is a single-arm, open phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, pharmacokinetics, and preliminary efficacy of FS-8002 and combination therapy in patients with advanced solid tumors
- Trial name
- NCT06832982
- Testing
- FS-8002 injection, Toripalimab Injection, Chemotherapy
- Where
- 10 sites in China
- Volunteers
- 66 people
- Sponsor
- Shanghai Pushi Medical Science Co. Ltd